IMMUNEONCO-B (01541): The first patient has been dosed in the phase II randomized and placebo-controlled trial of IMM0306 for the treatment of SLE.
Yiming Aongke-B (01541) announced that the Phase II randomized and placebo-controlled trial of IMM0306 for the treatment of systemic lupus erythematosus (SLE) has successfully administered the first dose to a patient. It is expected to recruit approximately 90 patients, who will be randomly assigned in a 1:1:1 ratio to three treatment groups to receive treatment with IMM0306 (doses of 1.2 mg/kg and 1.6 mg/kg) or placebo.
IMMUNEONCO-B(01541) issued an announcement that the phase II randomized placebo-controlled trial of IMM0306 for the treatment of systemic lupus erythematosus (SLE) has successfully dosed the first patient. It is expected to recruit approximately 90 patients, who will be randomly assigned in a 1:1:1 ratio to three treatment groups, receiving treatment with IMM0306 (doses of 1.2 mg/kg and 1.6 mg/kg) or placebo.
Related Articles
Zhaojin Mining (01818): Wang Yue has been appointed as Chairman, Executive Director, President, and Authorized Representative of the Company.
US Stock Market Move | AI application software stocks rise against the trend, ServiceNow (NOW.US) surges more than 4%
DUALITYBIO-B (09606) plans to repurchase up to $40 million worth of shares, and founder Zhu Zhongyuan plans to increase his shareholding by no more than $5 million.
Zhaojin Mining (01818): Wang Yue has been appointed as Chairman, Executive Director, President, and Authorized Representative of the Company.
US Stock Market Move | AI application software stocks rise against the trend, ServiceNow (NOW.US) surges more than 4%
DUALITYBIO-B (09606) plans to repurchase up to $40 million worth of shares, and founder Zhu Zhongyuan plans to increase his shareholding by no more than $5 million.
